**Supplementary Table 1. Characteristics of HIV/hepatitis B virus-coinfected patients in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS), overall and by availability of a serum/plasma sample.**

|  **No available serum/plasma Available serum/plasma** **Total (n=2265) sample (n=1648) sample (n=597)**  |
| --- |
| **Age (n, %)** |
| Median (years, IQR) 40 (34-48) 40 (33-47) 43 (37-49) |
| <40 years 1032 (46.0) 821 (49.8) 211 (35.3) |
| 40-49 years 790 (35.2) 543 (32.9) 247 (41.4)  |
| ≥50 years 423 (18.8) 284 (17.2) 139 (23.3) |
| **Male sex (n,** %) 1988 (88.6) 1451 (88.0) 537 (89.9)  |
| **Race (n, %)** |
| White 1018 (45.3) 765 (46.4) 253 (42.4) |
| Black or African American 1077 (48.0) 762 (46.2) 315 (52.8)  |
| Asian/Pacific Islander 55 (2.4) 44 (2.7) 11 (1.8) |
| Other or unknown 95 (4.2) 77 (4.7) 18 (3.0) |
| **Hispanic (n, %)**  158 (7.0) 120 (7.3) 38 (6.4)  |
| **History of alcohol abuse/dependence**† **(n, %)** 504 (22.4) 340 (20.6) 164 (27.5)  |
| **HIV transmission risk factors**‡ **(n, %)** |
| Men who have sex with men 1404 (70.6) 1008 (69.5) 396 (73.7)  |
| History of injection drug use 440 (19.6) 339 (20.6) 101 (16.9)  |
| Heterosexual contact 520 (23.2) 318 (19.3) 202 (33.8)  |
| **Hepatitis C virus infection status**§ **(n, %)** None 1797 (80.0) 1307 (79.3) 490 (82.1) + HCV Antibody, - HCV RNA and – HCV genotype 223 (9.9) 180 (10.9) 43 (7.2)  + HCV RNA or + HCV genotype 225 (10.2) 161 (9.8) 64 (10.7) |
| **Ever HBeAg positive**¶ **(n, %)** Yes 341 (15.2) 182 (11.0) 159 (26.6)  No 205 (9.1) 109 (6.6) 96 (16.1) No result prior to index date 1699 (75.7) 1357 (82.3) 342 (57.3)**HIV RNA**€ **(n, %)** |
| Median (cells/mm3, IQR) 7368 (50-79762) 17385 (75-101117) 269 (48-28167) |
| ≤500 copies/mL 797 (35.5) 486 (29.5) 311 (52.1)  |
| >500 copies/mL 1190 (53.0) 924 (56.1) 266 (44.6)No result within -365/+30 days of index date 258 (11.5) 238 (14.4) 20 (3.4) |
| **Absolute CD4+ cell count**€ **(n, %)** |
| Median (cells/mm3, IQR) 281.5 (104-491) 263 (93-478) 309 (137-524) |
| ≥500 cells/mm3 474 (21.1) 313 (19.0) 161 (27.0) |
| 200-499 cells/mm3 730 (32.5) 517 (31.4) 213 (35.7)  |
| <200 cells/mm3 756 (33.7) 561 (34.0) 195 (32.7)No result within -365/+30 days of index date 285 (12.7) 257 (15.6) 28 (4.7) |
| **On ART**¥ **(n, %)** 880 (39.2) 456 (27.7) 424 (71.0)  On at least one antiretroviral 1007 (44.5) 561 (34.0) 446 (74.7)**Receiving HBV-active antiretroviral**¥ **(n, %)** 309 (13.8) 200 (12.1) 109 (18.3) **Specific HBV-active antiretroviral(s)** ¥ ***(*n, %*)***Lamivudine or Emtricitabine alone 193 (62.5) 127 (63.5) 66 (60.6)Tenofovir alone 55 (17.8) 38 (19.0) 17 (15.6)Tenofovir + (Lamivudine or Emtricitabine) 61 (19.7) 35 (17.5) 26 (23.9)  |
| **On entecavir**¥ **(n, %)** 18 (0.8) 4 (0.2) 14 (2.3) **FIB-4 score**°<1.45 (no cirrhosis) 1083 (48.2) 763 (46.3) 320 (53.6) 1.45-3.25 (inconclusive) 623 (27.8) 436 (26.5) 187 (31.3)  >3.25 (cirrhosis/advanced fibrosis) 312 (13.9) 240 (14.6) 72 (12.1) No result within -365/+30 days of index date 227 (10.1) 209 (12.7) 18 (3.0) |

Abbreviations: ART=antiretroviral therapy; FIB-4=fibrosis 4; HBeAg=hepatitis B e antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus; IQR=interquartile range; IU=international units; mL=milliliter; RNA=ribonucleic acid; µL=microliter.

Index date refers to the date of specimen collection.

Age was measured as the date of specimen collection minus July 1st of the birth year.

Sex and race/ethnicity were collected upon enrollment into CNICS.

†History of alcohol abuse/dependence were defined as ever having an inpatient or outpatient diagnosis of alcohol abuse/dependence based on the presence of at least one International Classification of Diseases code for alcohol abuse/dependence.

‡History of MSM status, intravenous drug use, and heterosexual contact were defined based on patient self-reporting of ever having engaged in the respective behavior. MSM status was determined from the subset of males. These risk factors are not mutually exclusive.

§Hepatitis C virus infection status was determined by: 1) detectable HCV RNA or HCV genotype or 2) positive HCV antibody and undetectable HCV RNA and genotype

¶HBeAg status was determined as ever having a positive HBeAg on or prior to the specimen collection date.

€Laboratory data were collected within 365 days prior and 30 days after the specimen collection date. If multiple laboratory results were available within -365/+30 days of the specimen collection date, the lab value closest to the specimen collection date was used.

¥ART was measured as a combination of 3 antiretroviral agents from at least two drug classes or a triple nucleoside/nucleotide reverse transcriptase inhibitor regimen. ART and HBV-active antiretroviral therapy use was determined based on the reported ART regimen documented at the time of specimen collection.

°FIB-4 score was by: (age [years] x AST [U/L])/(platelet count [109/L] x (ALT [U/L]1/2) using laboratory values closest to within -365/+30 days of the specimen collection date

**Supplementary Table 2. Prevalence (95% confidence interval) of hepatitis delta virus IgG antibody-positivity, by Center for AIDS Research Network of Integrated Clinical Systems (CNICS) site.**

|  |  |  |
| --- | --- | --- |
| **CNICS Clinical Site** | **Prevalence of** **HDV IgG Antibody** | **95% Confidence Interval**\* |
| Case Western Reserve Univ (n=58)  | 0.0% | 0.0-6.1% |
| Fenway Health/Harvard Univ (n=20) | 5.0% | 0.1-25.0% |
| Johns Hopkins Univ (n=76) | 3.9% | 0.8-11.1% |
| Univ of Alabama (n=88) | 1.1% | 0.0-6.2% |
| Univ of CA San Diego (n=114) | 8.8% | 4.3-15.5% |
| Univ of CA San Francisco (n=19) | 0.0% | 0.0-17.6% |
| Univ of North Carolina (n=162) | 3.1% | 1.0-7.1% |
| Univ of Washington (n=60) | 6.7% | 1.9-16.2% |

Abbreviations: CNICS=Center for AIDS Research network of Integrated Clinical Systems

\*Note: The above table calculates exact 95% confidence intervals at the site level to accommodate zero prevalence at several of the sites.